Merck & Co. is undervalued with strong oncology growth, key R&D investments, and shareholder returns. Click here to read an ...

US job openings in research and development are plunging as the Trump administration ramps up funding cuts to government ...

Merck KGaA's recent stock dip of 13% might scream trouble, but under the hood, things look remarkably solid. Despite a ...

Trump has claimed the move could cut US drug prices by 30 to 80 percent. However, according to German consultancy ...

Merck & Co. got a lukewarm “neutral” rating from Citigroup, along with a price target drop from $115 to $84. Other analysts ...

As has been the case for several quarters now, Merck KGaA’s life science business continues to serve as a weathervane for the ...

We believe that Merck KGaA enjoys a narrow moat, driven by intangible assets and switching costs which are prevalent in its Life Science and Electronics businesses. A few acquisitions to fill gaps in ...

Investing.com -- Merck KGaA (ETR: MRCG) on Thursday revised its 2025 guidance due to foreign-exchange challenges and tariff ...

The company posted better-than-expected earnings as industrial business profit grew 29%. Deutsche Telekom Lifts Guidance After Revenue Beats Market Expectations The full-year outlook raise from the ...

The German life-sciences and electronics company slashed its full-year guidance on the back of challenging macroeconomic ...

Total cost of revenue was $6.8 million in the first quarter of 2025, a decrease of 5% compared to $7.1 million in the first ...

Germany's Merck says in late-stage discussions to buy SpringWorks for $3.5 billion Germany's Merck KGaA said on Thursday ... and it lowered its outlook for the full year due to higher-than ...